Risk of Inadequate Revenue Recognition Controls for Direct-Shipment Medical Device Transactions
First written in FY2023. 1 of 2 entries say "Mitigated", first in FY2026. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026MitigatedAnnual report
「Of the ¥63,868 million in sales of the medical equipment distribution business for the consolidated fiscal year, sales of equipment to peer companies and others accounted for approximately 5.1%. Among these transactions, those in which products are shipped directly from suppliers to medical institutions are relatively difficult for the Company to verify because it does not directly handle the shipment of the products. To reduce this risk, the Company is clarifying procedures for verifying the existence of the goods and matching external evidence, such as delivery notes issued by suppliers, in order to assess the validity of revenue recognition.」
The proportion of sales of supplies to peer companies and other parties involved in direct-shipment transactions was 5.1%, down from approximately 5.6% in the previous disclosure. Risk mitigation measures, including reconciliation with external documentary evidence and procedures to verify the existence of transactions, are also continuing. - FY2023First statedAnnual report
「Of the ¥57,840 million in revenue from the medical device sales business for the consolidated fiscal year, approximately 5.6% consisted of equipment sales to companies in the same industry and other parties. In particular, transactions in which products are shipped directly from suppliers to medical institutions are relatively difficult to verify because the Company does not directly handle shipment. To reduce this risk, the Company reconciles transactions with external documentation such as delivery notes issued by suppliers and clarifies procedures for verifying the existence of the goods to assess the appropriateness of revenue recognition.」
For direct-shipment transactions, the Company disclosed that sales of equipment to peer companies and others accounted for approximately 5.6% of the medical equipment distribution business's ¥57,840 million in sales, that verifying the facts supporting revenue recognition is difficult, and that measures include matching transactions against external evidence.